Given the major impact of the APOE ε4 allele on AD risk and the accelerated cognitive decline and spread of amyloid and tau pathologies associated with this allele, there is a consensus in a large research consortium group that lowering the apoE4 protein should be a therapeutic target for the treatment of AD [205]. This evidence concerns the gene MAPT and Alzheimer disease.